ReviewFrontiers in oncology2020
Molecular Mechanism and Approach in Progression of Meningioma.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Preoperative prediction of meningioma grade based on synthetic MRI quantitative T1 and T2 mapping.Japanese journal of radiology · 2026Article
- Article
- Article
- Clinical application of intraoperative ultrasound superb microvascular imaging in brain tumors resections: contributing to the achievement of total tumoral resection.BMC medical imaging · 2024Article
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why?Cancers · 2022Review
- Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives.Frontiers in oncology · 2022Review
- Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature.Frontiers in oncology · 2022Review
- M2-Macrophage-Derived Exosomes Promote Meningioma Progression through TGF-Journal of immunology research · 2022Article
- Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma.International journal of molecular sciences · 2021Review
- The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningioma is the most common tumor of the central nervous system, most of which is benign. Even after complete resection, a high rate of recurrence of meningioma is observed. From in-depth study of its pathogenesis, it has been found that a number of chromosomal variations and abnormal molecular signals are closely related to the occurrence and development of malignancy in meningioma, which may provide the theoretical basis and potential direction for accurate and targeted treatment. We have reviewed advances in chromosomal variations and molecular mechanisms involved in the progression of meningioma, and have highlighted the association with malignant biological behavior including cell proliferation, angiogenesis, increased invasiveness, and inhibition of apoptosis. In addition, the chemotherapy of meningioma is summarized and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.